SCHEMBL22444804

SCHEMBL22444804

Fc1cc(Cl)cc([C@H]2CCON2)c1

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPM5 Q9NZQ8 7/20 0.35
TRPM4 Q8TD43 2/20 0.35
RIPK1 Q13546 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31087334 1.00 TRPM5 (0.35) TRPM5TRPM4RIPK1
SCHEMBL25189077 1.00 TRPM5 (0.35) TRPM5TRPM4RIPK1
SCHEMBL22444805 1.00 TRPM5 (0.35) TRPM5TRPM4RIPK1
SCHEMBL21783593 0.88
SCHEMBL22233087 0.88
SCHEMBL22256503 0.88
Hydrochloric Acid SCHEMBL30339018 0.86
SCHEMBL25819471 0.81
SCHEMBL27054181 0.80 EPAS1 (0.36)
SCHEMBL29433917 0.80 NOTUM (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4631507-A2 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT Voronoi Inc. (KR) 2025-10-15 EP disclosed
EP-3943491-B1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT VORONOI INC (KR) 2025-06-18 EP disclosed
US-12157730-B2 Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component VORONOI INC. (KR) 2024-12-03 US disclosed
US-12152021-B2 Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component VORONOI INC. (KR) 2024-11-26 US disclosed
CN-114605400-B Heteroaryl derivatives, process for preparing the same, and pharmaceutical compositions containing the same as active ingredient 株式会社沃若诺伊 2024-09-10 CN disclosed
US-20240150337-A1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT VORONOIBIO INC. (KR) 2024-05-09 US disclosed
CN-115838369-A Heteroaryl derivatives, process for preparing the same, and pharmaceutical composition containing the same as active ingredient 株式会社沃若诺伊 2023-03-24 CN disclosed
CN-113993866-B Heteroaryl derivatives, process for preparing the same, and pharmaceutical composition containing the same as active ingredient 株式会社沃若诺伊 2022-10-28 CN disclosed
US-11466000-B2 Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component VORONOI INC. (KR) 2022-10-11 US disclosed
US-20220289733-A1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT VORONOI INC. (KR) 2022-09-15 US disclosed
CN-114605400-A Heteroaryl derivatives, process for preparing the same, and pharmaceutical composition containing the same as active ingredient 株式会社沃若诺伊 2022-06-10 CN disclosed
US-20220162203-A1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT VORONOI INC. (KR) 2022-05-26 US disclosed
CN-113993866-A Heteroaryl derivatives, process for preparing the same, and pharmaceutical composition containing the same as active ingredient 株式会社沃若诺伊 2022-01-28 CN disclosed
EP-3943491-A1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT Voronoi Inc. (KR) 2022-01-26 EP disclosed
WO-2020190119-A1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT 주식회사 보로노이 2020-09-24 WO disclosed
WO-2020190119-A1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT 주식회사 보로노이 2020-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157730-B2 Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component ERBB4, ERBB2, EGFR TRPM5 2534/4885TRPM4 806/4885RIPK1 4240/4885
US-20220289733-A1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT ERBB4, ERBB2, EGFR TRPM5 2534/4885TRPM4 806/4885RIPK1 4240/4885
US-20220162203-A1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT ERBB4, ERBB2, EGFR TRPM5 2534/4885TRPM4 806/4885RIPK1 4240/4885
US-11466000-B2 Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component ERBB4, ERBB2, EGFR TRPM5 2534/4885TRPM4 806/4885RIPK1 4240/4885
US-12152021-B2 Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component ERBB4, ERBB2, EGFR TRPM5 2534/4885TRPM4 806/4885RIPK1 4240/4885
US-20240150337-A1 HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT ERBB4, ERBB2, EGFR TRPM5 2534/4885TRPM4 806/4885RIPK1 4240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.